fluticasone propionate
Xhance
Pharmaceutical company: Optinose, Inc.
NEW INDICATION & DOSAGE
Chronic rhinosinusitis with or without polyps
Adults: 1 spray (93 mcg/spray) in each nostril b.i.d. May increase to maximum dose of 2 sprays in each nostril b.i.d.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
maralixibat
Livmarli
Pharmaceutical company: Mirum Pharmaceuticals
NEW INDICATION & DOSAGE
Cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)
Adults and children age 5 and older: Initially, 285 mcg/kg PO once daily in the morning. Increase as tolerated to 285 mcg/kg b.i.d., then to 428 mcg/kg b.i.d., and then to recommended dosage of 570 mcg/kg PO b.i.d. 30 minutes before a meal. The maximum dose is 38 mg daily.
Adjust-a-dose: Decrease dosage or interrupt therapy for new liver function test (LFT) abnormalities or GI adverse reactions. When LFT values return to baseline or stabilize at new baseline values, consider restarting at last tolerated dose, and increase as tolerated. If LFT abnormalities or GI reactions recur, or signs and symptoms consistent with clinical hepatitis, portal hypertension, or liver decompensation (variceal hemorrhage, ascites, hepatic encephalopathy) occur, discontinue therapy. This drug isn't recommended in a subgroup of PFIC type 2 patients with nonfunctional or complete absence of bile salt export pump protein.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
alirocumab
Praluent
Pharmaceutical company: Regeneron Pharmaceuticals
NEW INDICATION & DOSAGE
Adjunct to diet and other LDL-C-lowering therapies in patients with heterozygous familial hypercholesterolemia to reduce LDL-C
Children age 8 and older weighing 50 kg or more: 300 mg subcut every 4 weeks. If LDL-C reduction is inadequate, adjust dosage to 150 mg every 2 weeks.
Children age 8 and older weighing less than 50 kg: 150 mg subcut every 4 weeks. If LDL-C reduction is inadequate, adjust dosage to 75 mg subcut every 2 weeks.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
nivolumab
Opdivo
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
With cisplatin and gemcitabine, for unresectable or metastatic urothelial carcinoma (first-line treatment)
Adults: 360-mg IV infusion with cisplatin and gemcitabine on the same day every 3 weeks for up to 6 cycles; then 240-mg IV infusion every 2 weeks or 480-mg IV infusion every 4 weeks as a single agent until disease progression or unacceptable toxicity occurs, or up to 2 years from the first dose.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
rilpivirine
Edurant
Pharmaceutical company: Janssen Therapeutics
NEW FORMULATION
Tablets for oral suspension: 2.5 mg (Edurant Ped)
NEW INDICATION & DOSAGE
HIV-1 infection in patients who are antiretroviral-naive with HIV-1 RNA 100,000 copies/mL or less at start of therapy, in combination with other antiretrovirals
Children age 2 and older weighing 25 kg or more: 25 mg PO once daily.
Children age 2 and older weighing 20 kg to less than 25 kg: 15 mg (6 tablets for oral suspension) PO once daily.
Children age 2 and older weighing 14 kg to less than 20 kg: 12.5 mg (5 tablets for oral suspension) PO once daily.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
remdesivir
Veklury
Pharmaceutical company: Gilead Sciences, Inc.
NEW INDICATION & DOSAGE
Coronavirus disease 2019 (COVID-19) requiring hospitalization
Children age 28 days and older weighing 1.5 kg to less than 3 kg: Initiate therapy as soon as possible after diagnosis with 2.5 mg/kg-IV infusion on day 1, followed by maintenance dose of 1.25 mg/kg-IV infusion once daily starting on day 2 for 5 days in patients not requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). If no clinical improvement, may extend therapy 5 additional days. Give the drug for 10 days to patients requiring invasive mechanical ventilation or ECMO.
Children younger than 28 days weighing at least 1.5 kg to less than 3 kg: Initiate therapy as soon as possible after diagnosis with 2.5 mg/kg-IV infusion on day 1, followed by maintenance dose of 1.25 mg/kg-IV infusion once daily starting on day 2 for 5 days in patients not requiring invasive mechanical ventilation or ECMO. If no clinical improvement, may extend therapy 5 additional days. Give the drug for 10 days to patients requiring invasive mechanical ventilation or ECMO.
Adjust-a-dose: Consider discontinuing the drug if ALT level increases to greater than 10 times the upper limit of normal (ULN). Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation.
Nonhospitalized patients with mild to moderate COVID-19 at high risk for progression to severe COVID-19, including hospitalization or death
Children age 28 days and older weighing 1.5 kg to less than 3 kg: Initiate therapy as soon as possible after diagnosis and within 7 days of symptom onset with 2.5 mg/kg-IV infusion on day 1, followed by 1.25 mg/kg-IV infusion once daily on days 2 and 3.
Children younger than 28 days weighing at least 1.5 kg to less than 3 kg: Initiate therapy as soon as possible after diagnosis and within 7 days of symptom onset with 2.5 mg/kg-IV infusion on day 1, followed by 1.25 mg/kg-IV infusion once daily on days 2 and 3.
Adjust-a-dose: Consider discontinuing the drug if ALT level increases to greater than 10 times the ULN. Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
semaglutide
Wegovy
Pharmaceutical company: Novo Nordisk
NEW INDICATION & DOSAGE
To reduce the risk of major CV events (CV death, nonfatal MI, or nonfatal stroke) in patients with established CV disease and either obesity or overweight (Wegovy only)
Adults: Initially, 0.25 mg subcut once weekly for 4 weeks, then increase to 0.5 mg for 4 weeks, then 1 mg for 4 weeks, then 1.7 mg for 4 weeks, then to a 2.4-mg weekly maintenance dose.
Adjust-a-dose: If any dose is not initially tolerated, delay dose escalation for 4 weeks. If a 2.4-mg dose is not tolerated, decrease to maintenance dose of 1.7 mg. If the 1.7 mg dose is not tolerated, discontinue the drug.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
zanubrutinib
Brukinsa
Pharmaceutical company: BeiGene
NEW INDICATION & DOSAGE
With obinutuzumab, for relapsed or refractory follicular lymphoma (after two or more lines of systemic therapy)
Adults: 160 mg PO b.i.d. or 320 mg PO once daily until disease progression or unacceptable toxicity occurs.
Released: May 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer